{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:17:50Z","timestamp":1790824670153,"version":"4.1.0"},"reference-count":26,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK065988"],"award-info":[{"award-number":["P30DK065988"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BOUCHE19R0"],"award-info":[{"award-number":["BOUCHE19R0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2023,10,18]]},"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1183\/23120541.00746-2023","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T15:15:35Z","timestamp":1699542935000},"page":"00746-2023","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Cystic fibrosis airway inflammation enables elexacaftor\/tezacaftor\/ivacaftor-mediated rescue of N1303K<i>CFTR<\/i>mutation"],"prefix":"10.1183","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9435-0321","authenticated-orcid":false,"given":"Martina","family":"Gentzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1142-4493","authenticated-orcid":false,"given":"Brooke","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Cholon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3419-2613","authenticated-orcid":false,"given":"Charissa W.","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"McKinzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Despotes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Boyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Quinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8081-2986","authenticated-orcid":false,"suffix":"Jr","given":"Charles R.","family":"Esther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5247-7060","authenticated-orcid":false,"given":"Carla M.P.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"2024101712084327000_10.1.00746-2023.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2024101712084327000_10.1.00746-2023.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2024101712084327000_10.1.00746-2023.3","unstructured":"US Food and Drug Administration . FDA approves new breakthrough therapy for cystic fibrosis. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-breakthrough-therapy-cystic-fibrosis. Date last updated: 21 October 2019."},{"key":"2024101712084327000_10.1.00746-2023.4","unstructured":"European Medicines Agency . Kaftrio. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kaftrio. Date last updated: 26 July 2023."},{"key":"2024101712084327000_10.1.00746-2023.5","unstructured":"European Commission . Kaftrio. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1468.htm. Date last updated: 4 September 2023."},{"key":"2024101712084327000_10.1.00746-2023.6","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101712084327000_10.1.00746-2023.7","unstructured":"Cystic Fibrosis Foundation . Patient registry. https:\/\/www.cff.org\/medical-professionals\/patient-registry."},{"key":"2024101712084327000_10.1.00746-2023.8","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1091\/mbc.E20-11-0688","article-title":"DNAJB12 and Hsp70 triage arrested intermediates of N1303K-CFTR for endoplasmic reticulum-associated autophagy","volume":"32","author":"He","year":"2021","journal-title":"Mol Biol Cell"},{"key":"2024101712084327000_10.1.00746-2023.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01192-2015"},{"key":"2024101712084327000_10.1.00746-2023.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02774-2020"},{"key":"2024101712084327000_10.1.00746-2023.11","doi-asserted-by":"crossref","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"2024101712084327000_10.1.00746-2023.12","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00716-2021"},{"key":"2024101712084327000_10.1.00746-2023.13","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1164\/rccm.202101-0090LE","article-title":"Elexacaftor\/tezacaftor\/ivacaftor improved clinical outcomes in a patient with N1303K-CFTR based on in vitro experimental evidence","volume":"204","author":"Huang","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101712084327000_10.1.00746-2023.14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201706-1139oc"},{"key":"2024101712084327000_10.1.00746-2023.15","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.3390\/cells10113260","article-title":"Impact of airway inflammation on the efficacy of CFTR modulators","volume":"10","author":"Ribeiro","year":"2021","journal-title":"Cells"},{"key":"2024101712084327000_10.1.00746-2023.16","doi-asserted-by":"crossref","first-page":"628722","DOI":"10.3389\/fphar.2021.628722","article-title":"Airway epithelial inflammation in vitro augments the rescue of mutant CFTR by current CFTR modulator therapies","volume":"12","author":"Gentzsch","year":"2021","journal-title":"Front Pharmacol"},{"key":"2024101712084327000_10.1.00746-2023.17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01133-2018"},{"key":"2024101712084327000_10.1.00746-2023.18","doi-asserted-by":"crossref","first-page":"e150398","DOI":"10.1172\/JCI150398","article-title":"Inflammatory cytokines TNF-alpha and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators","volume":"131","author":"Rehman","year":"2021","journal-title":"J Clin Invest"},{"key":"2024101712084327000_10.1.00746-2023.19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcf.2003.12.009","article-title":"Severe CF manifestation with anaemia and failure to thrive in a 394delTT homozygous patient","volume":"3","author":"Kahre","year":"2004","journal-title":"J Cyst Fibros"},{"key":"2024101712084327000_10.1.00746-2023.20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.155259"},{"key":"2024101712084327000_10.1.00746-2023.21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008680"},{"key":"2024101712084327000_10.1.00746-2023.22","doi-asserted-by":"crossref","first-page":"102258","DOI":"10.1016\/j.coph.2022.102258","article-title":"Functional role of the ER stress transducer IRE1\u03b1 in CF airway epithelial inflammation","volume":"65","author":"Ribeiro","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"2024101712084327000_10.1.00746-2023.23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18010118"},{"key":"2024101712084327000_10.1.00746-2023.24","doi-asserted-by":"crossref","first-page":"114866","DOI":"10.1016\/j.addr.2023.114866","article-title":"Air-liquid interface cultures to model drug delivery through the mucociliary epithelial barrier","volume":"198","author":"Lee","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"2024101712084327000_10.1.00746-2023.25","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00041.2006"},{"key":"2024101712084327000_10.1.00746-2023.26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3390\/jpm11080729","article-title":"Sweat chloride testing and nasal potential difference (NPD) are primary outcome parameters in treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators","volume":"11","author":"Sermet-Gaudelus","year":"2021","journal-title":"J Pers Med"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00746-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:30:29Z","timestamp":1740375029000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00746-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,15]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1183\/23120541.00746-2023"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00746-2023","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]}}}